(VIANEWS) – Saratoga Investment Corp New (SAR), StoneCastle Financial Corp (BANX), CrossFirst Bankshares (CFB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Saratoga Investment Corp New (SAR)
45.3% sales growth and 4.09% return on equity
Saratoga Investment Corp. is a business development company specializing in leveraged and management buyouts, acquisition financings, growth financings, recapitalization, debt refinancing, and transitional financing transactions at the lower end of middle market companies. It structures its investments as debt and equity by investing through first and second lien loans, mezzanine debt, co-investments, select high yield bonds, senior secured bonds, unsecured bonds, and preferred and common equity. The firm prefers to invest in aerospace, automotive aftermarket and services, business products and services, consumer products and services, education, environmental services, industrial services, financial services, food and beverage, healthcare products and services, logistics, distribution, manufacturing, restaurants services, food services, software services, technology services, specialty chemical, media and telecommunications. It seeks to invest in the United States. The firm primarily invests $5 million to $50 million in companies having EBITDA of $2 million or greater and revenues of $8 million to $250 million. The firm prefer to take a majority stake. It invests through direct lending as well as participation in loan syndicates. The firm was formerly known as GSC Investment Corp. Saratoga Investment Corp. is based in New York, New York with an additional office in Florham Park, New Jersey.
Earnings Per Share
As for profitability, Saratoga Investment Corp New has a trailing twelve months EPS of $2.89.
PE Ratio
Saratoga Investment Corp New has a trailing twelve months price to earnings ratio of 8.66. Meaning, the purchaser of the share is investing $8.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.09%.
Moving Average
Saratoga Investment Corp New’s value is below its 50-day moving average of $26.38 and above its 200-day moving average of $24.70.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 11.4% and 766.7%, respectively.
Sales Growth
Saratoga Investment Corp New’s sales growth is 39.8% for the present quarter and 45.3% for the next.
2. StoneCastle Financial Corp (BANX)
37.9% sales growth and 3.56% return on equity
ArrowMark Financial Corp. is a closed-end balanced mutual fund launched and managed by ArrowMark Asset Management, LLC. It invests in public equity and fixed income markets of global region. For its equity portion, the fund invests in stocks of companies operating across financials, banks sectors. It invests in growth and value stocks of companies across diversified market capitalization. For its fixed income portion, the fund invests in debt and subordinated debt, structured notes and securities, regulatory capital securities which are rated below investment grade. ArrowMark Financial Corp. was formed on February 7, 2013 and is domiciled in the United States.
Earnings Per Share
As for profitability, StoneCastle Financial Corp has a trailing twelve months EPS of $0.8.
PE Ratio
StoneCastle Financial Corp has a trailing twelve months price to earnings ratio of 22.5. Meaning, the purchaser of the share is investing $22.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.56%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 22, 2023, the estimated forward annual dividend rate is 1.56 and the estimated forward annual dividend yield is 9.24%.
3. CrossFirst Bankshares (CFB)
22.4% sales growth and 9.65% return on equity
Earnings Per Share
As for profitability, CrossFirst Bankshares has a trailing twelve months EPS of $1.21.
PE Ratio
CrossFirst Bankshares has a trailing twelve months price to earnings ratio of 8.5. Meaning, the purchaser of the share is investing $8.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.65%.
4. United Therapeutics Corporation (UTHR)
17.1% sales growth and 16.86% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $15.52.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 14.64. Meaning, the purchaser of the share is investing $14.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.86%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16%, now sitting on 1.86B for the twelve trailing months.
Yearly Top and Bottom Value
United Therapeutics Corporation’s stock is valued at $227.19 at 11:22 EST, way under its 52-week high of $283.09 and way higher than its 52-week low of $173.22.
Moving Average
United Therapeutics Corporation’s value is under its 50-day moving average of $239.17 and below its 200-day moving average of $240.35.
5. Rogers Corporation (ROG)
12.5% sales growth and 6.62% return on equity
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. It operates through Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS), and Other segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solutions for applications in electric and hybrid electric vehicles (EV/HEV), wireless infrastructure, automotive, telematics and thermal solutions, aerospace and defense, mass transit, clean energy, connected devices, and wired infrastructure markets. This segment sells its products under the curamik, ROLINX, RO4000, RO3000, RT/duroid, CLTE Series, TMM, AD Series, DiClad, CuClad Series, Kappa, COOLSPAN, TC Series, 92ML, IsoClad, MAGTREX, XTremeSpeed RO1200, IM Series, 2929 Bondply, 3001 Bondply Film, and SpeedWave names. The EMS segment provides engineered material solutions, including polyurethane and silicone materials used in cushioning, gasketing, sealing, and vibration management applications; customized silicones used in flex heater and semiconductor thermal applications; and polytetrafluoroethylene and ultra-high molecular weight polyethylene materials used in wire and cable protection, electrical insulation, conduction and shielding, hose and belt protection, vibration management, cushioning, gasketing and sealing, and venting applications. This segment sells its products under the PORON, BISCO, DeWAL, ARLON, eSORBA, Griswold, XRD, Silicone Engineering, and R/bak names. The Other segment provides elastomer components; and elastomer floats for level sensing in fuel tanks, motors, and storage tanks for applications in the general industrial and automotive markets under the ENDUR and NITROPHYL names. Rogers Corporation was founded in 1832 and is headquartered in Chandler, Arizona.
Earnings Per Share
As for profitability, Rogers Corporation has a trailing twelve months EPS of $3.62.
PE Ratio
Rogers Corporation has a trailing twelve months price to earnings ratio of 44.94. Meaning, the purchaser of the share is investing $44.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.62%.
Yearly Top and Bottom Value
Rogers Corporation’s stock is valued at $162.83 at 11:22 EST, way below its 52-week high of $274.51 and way higher than its 52-week low of $98.45.
Moving Average
Rogers Corporation’s worth is higher than its 50-day moving average of $148.41 and way below its 200-day moving average of $191.20.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.8%, now sitting on 977.92M for the twelve trailing months.
Volume
Today’s last reported volume for Rogers Corporation is 367680 which is 21.23% above its average volume of 303281.
6. Autohome (ATHM)
8% sales growth and 7.44% return on equity
Autohome Inc. operates as an online destination for automobile consumers in the People's Republic of China. The company, through its websites, autohome.com.cn and che168.com, and its mobile applications and mini apps, delivers interactive content and tools to automobile consumers. It provides media services, including automaker advertising services and regional marketing campaigns; and leads generation services comprising dealer subscription services, advertising services for individual dealers, and used automobile listing and other platform-based services. The company also offers Autohome Mall, an online transaction platform for users to review automotive-related information, purchase coupons offered by automakers for discounts, and make purchases to complete the transaction; data products; and online bidding platform for used automobiles, as well as collects commissions for facilitating transactions of auto-financing and insurance products on its platform. The company was formerly known as Sequel Limited and changed its name to Autohome Inc. in October 2011. Autohome Inc. was incorporated in 2008 and is headquartered in Beijing, the People's Republic of China.
Earnings Per Share
As for profitability, Autohome has a trailing twelve months EPS of $2.01.
PE Ratio
Autohome has a trailing twelve months price to earnings ratio of 15.35. Meaning, the purchaser of the share is investing $15.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.44%.
Volume
Today’s last reported volume for Autohome is 908447 which is 38.09% above its average volume of 657856.
Moving Average
Autohome’s value is under its 50-day moving average of $33.63 and below its 200-day moving average of $33.00.
7. Telefonica Brasil, S.A. ADS (VIV)
7.5% sales growth and 8.03% return on equity
Telef̫nica Brasil S.A., together with its subsidiaries, provides mobile and fixed telecommunications services to residential and corporate customers in Brazil. Its fixed line services portfolio includes local, domestic long-distance, and international long-distance calls; and mobile portfolio comprises voice and broadband internet access through 3G, 4G, 4.5G, and 5G as well as mobile value-added services and wireless roaming services. The company also offers data services, including broadband and mobile data services. In addition, it provides pay TV services through direct to home satellite technology, IPTV, and cable, as well as pay-per-view and video on demand services; network services, such as rental of facilities; other services comprising internet access, private network connectivity, computer equipment leasing, extended service, caller identification, voice mail, cellular blocker, and others; wholesale services, including interconnection services to users of other network providers; and digital services, such as entertainment, cloud, and security and financial services. Further, the company offers multimedia communication services, which include audio, data, voice and other sounds, images, texts, and other information, as well as sells devices, such as smartphones, broadband USB modems, and other devices. Additionally, it provides telecommunications solutions and IT support to various industries, such as retail, manufacturing, services, financial institutions, government, etc. It markets and sells its solutions through own stores, dealers, retail and distribution channels, door-to-door sales, and outbound tele sales. The company was formerly known as Telecomunica̵̤es de Ṣo Paulo S.A. РTELESP and changed its name to Telef̫nica Brasil S.A. in October 2011. The company was incorporated in 1998 and is headquartered in Ṣo Paulo, Brazil.
Earnings Per Share
As for profitability, Telefonica Brasil, S.A. ADS has a trailing twelve months EPS of $0.52.
PE Ratio
Telefonica Brasil, S.A. ADS has a trailing twelve months price to earnings ratio of 14.59. Meaning, the purchaser of the share is investing $14.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.03%.
8. AmerisourceBergen (ABC)
5.5% sales growth and 501.95% return on equity
AmerisourceBergen Corporation sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturer. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segments also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Earnings Per Share
As for profitability, AmerisourceBergen has a trailing twelve months EPS of $-15.76.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 501.95%.
